Taenia solium cysticercosis. (Q33876194)

29 July 2017

1 reference

title

Taenia solium cysticercosis. (English)

1 reference

29 July 2017

0 references

0 references

Garcia HH

1

1 reference

PubMed ID

10738675

29 July 2017

Del Brutto OH

series ordinal

2

1 reference

29 July 2017

1 March 2000

1 reference

Infectious Disease Clinics of North America

29 July 2017

1 reference

29 July 2017

14

1 reference

29 July 2017

1

1 reference

29 July 2017

97-119, ix

1 reference

Immunodiagnosis of taeniasis by coproantigen detection.

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Mass chemotherapy for intestinal Taenia solium infection: effect on prevalence in humans and pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Epidemiology of intestinal taeniasis in four, rural, Guatemalan communities.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Neurocysticercosis: regression of a fourth ventricular cyst with praziquantel

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Surgical considerations in treatment of intraventricular cysticercosis. An analysis of 45 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Etiology of epilepsy a prospective study of 210 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized, placebo-controlled, double blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

The racemose form of cerebral cysticercosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Phenytoin and carbamazepine decreased oral bioavailability of praziquantel

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Cysticercosis of the spinal cord

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Cerebrovascular complications of neurocysticercosis. Clinical and neuroimaging spectrum.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Radiology of cysticercosis of the central nervous system including computed tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Cysticerciasis and epilepsy: a clinical and serological study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Results of surgical treatment of neurocysticercosis in 69 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Single-day praziquantel therapy for neurocysticercosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Single-day praziquantel versus 1-week albendazole for neurocysticercosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Epilepsy due to neurocysticercosis: analysis of 203 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Albendazole therapy for giant subarachnoid cysticerci

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Therapy for neurocysticercosis: a reappraisal.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Albendazole therapy for subarachnoid and ventricular cysticercosis. Case report

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Neurocysticercosis: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Proposal of diagnostic criteria for human cysticercosis and neurocysticercosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Cysticercosis and cerebrovascular disease: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

The use of albendazole in patients with single lesions enhanced on contrast CT.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Albendazole therapy for subarachnoid cysticerci: clinical and neuroimaging analysis of 17 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Epidemiologic study and control of Taenia solium infections with praziquantel in a rural village of Mexico

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Epidemiology of taeniasis and cysticercosis in a Peruvian village. The Cysticercosis Working Group in Peru

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Parenchymal neurocysticercosis: follow-up and staging by MRI

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Mechanisms of hydrocephalus in cerebral cysticercosis: implications for therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Heavy nonencephalitic cerebral cysticercosis in tapeworm carriers. The Cysticercosis Working Group in Perú.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Cysticercosis as a major cause of epilepsy in Peru. The Cysticercosis Working Group in Peru (CWG)

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Human and porcine Taenia solium infection in a village in the highlands of Cusco, Peru. The Cysticercosis Working Group in Peru.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Cysticercosis Working Group in Peru.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Factors associated with Taenia solium cysticercosis: analysis of nine hundred forty-six Peruvian neurologic patients. Cysticercosis Working Group in Peru (CWG).

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Clinical significance of neurocysticercosis in endemic villages. The Cysticercosis Working Group in Peru.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

A specific antigen-detection ELISA for the diagnosis of human neurocysticercosis. The Cysticercosis Working Group in Peru

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Discrepancies between cerebral computed tomography and western blot in the diagnosis of neurocysticercosis. The Cysticercosis Working Group in Peru (Clinical Studies Coordination Board).

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

A Taenia solium oncosphere protein homologous to host-protective Taenia ovis and Taenia saginata 18 kDa antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Effective, single-dose treatment or porcine cysticercosis with oxfendazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Treatment of porcine cysticercosis with albendazole

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Treatment of porcine cysticercosis with oxfendazole: a dose-response trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Use of sentinel pigs to monitor environmental Taenia solium contamination. The Cysticercosis Working Group in Peru (CWG).

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Cysticercosis in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Vaccination against ovine cysticercosis using a defined recombinant antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Dexamethasone increases plasma levels of albendazole

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Transaqueductal migration of a neurocysticercus cyst. Case report

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Cerebrospinal fluid formula in patients with central nervous system infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Intraventricular cysticercosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Diagnosis of intraventricular and cisternal cysticercosis by computerized tomography with positive intraventricular contrast medium.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Cysticercosis cerebri. Review of 127 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Effect of anticysticercal treatment on the prognosis of epilepsy in neurocysticercosis: a pilot trial

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Neurocysticercosis as the main cause of late-onset epilepsy in Mexico.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Computed tomography (CT) in parenchymatous cerebral cysticercosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

A new immunologic test for CNS cysticercosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Neurocysticercosis--a review of 231 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Seroprevalence of cysticercosis in an Orthodox Jewish community

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Distribution of hydatidosis and cysticercosis in different Peruvian populations as demonstrated by an enzyme-linked immunoelectrotransfer blot (EITB) assay. The Cysticercosis Working Group in Peru (CWG).

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

An endoscopic approach to cysticercosis cysts of the posterior third ventricle

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Cysticercosis of the nervous system; diagnosis by means of the spinal fluid complement fixation test

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Neurocysticercosis in persons with epilepsy in Medellín, Colombia. The Neuroepidemiological Research Group of Antioquia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Etiology and management of single small CT lesions in patients with seizures: understanding a controversy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Cysticercotic encephalitis: a severe form in young females

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

ELISA in the diagnosis of neurocysticercosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Differential diagnosis between ventriculitis and fourth ventricle cyst in neurocysticercosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Development and evaluation of a health education intervention against Taenia solium in a rural community in Mexico.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Neurocysticercosis in an Orthodox Jewish community in New York City

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Community-based epidemiological investigations of cysticercosis due to Taenia solium: comparison of serological screening tests and clinical findings in two populations in Mexico.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Neurocysticercosis in Houston, Texas. A report of 112 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Albendazole vs praziquantel for therapy for neurocysticercosis. A controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Therapy of parenchymal brain cysticercosis with praziquantel.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Hydrocephalus secondary to cysticercotic arachnoiditis. A long-term follow-up review of 92 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Short course of albendazole therapy for neurocysticercosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

A new shunt for hydrocephalus that relies on CSF production rather than on ventricular pressure: initial clinical experiences.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Cerebral cysticercosis in Poland. Clinical symptoms and operative results in 132 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Effects of prednisone on ventriculoperitoneal shunt function in hydrocephalus secondary to cysticercosis: a preliminary study.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Therapy for neurocysticercosis. Comparison between albendazole and praziquantel

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Praziquantel treatment of porcine brain and muscle Taenia solium cysticercosis. 3. Effect of 1-day treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

The course of seizures after treatment for cerebral cysticercosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Plasma levels of praziquantel decrease when dexamethasone is given simultaneously.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Disseminated cysticercosis. New observations, including CT scan findings and experience with treatment by praziquantel

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

Neurocysticercosis: a major cause of neurological disease worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

The relationship of antibody levels to the clinical spectrum of human neurocysticercosis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2805%2970220-8

7 January 2021

10.1016/S0891-5520(05)70220-8

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10738675